Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade

Yi Feng Gu, Shannon Cohn, Alana Christie, Tiffani McKenzie, Nicholas Wolff, Quyen N. Do, Ananth J Madhuranthakam, Ivan Pedrosa, Tao Wang, Anwesha Dey, Meinrad Busslinger, Xian-Jin Xie, Robert E Hammer, Renee M McKay, Payal Kapur, James B Brugarolas

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Clear cell renal cell carcinoma (ccRCC) is characterized by BAP1 and PBRM1 mutations, which are associated with tumors of different grade and prognosis. However, whether BAP1 and PBRM1 loss causes ccRCC and determines tumor grade is unclear. We conditionally targeted Bap1 and Pbrm1 (with Vhl) in the mouse using several Cre drivers. Sglt2 and Villin proximal convoluted tubule drivers failed to cause tumorigenesis, challenging the conventional notion of ccRCC origins. In contrast, targeting with PAX8, a transcription factor frequently overexpressed in ccRCC, led to ccRCC of different grades. Bap1-deficient tumors were of high grade and showed greater mTORC1 activation than Pbrm1-deficient tumors, which exhibited longer latency. Disrupting one allele of the mTORC1 negative regulator, Tsc1, in Pbrm1-deficient kidneys triggered higher grade ccRCC. This study establishes Bap1 and Pbrm1 as lineage-specific drivers of ccRCC and histologic grade, implicates mTORC1 as a tumor grade rheostat, and suggests that ccRCCs arise from Bowman capsule cells. SIGnIFICAnCE: Determinants of tumor grade and aggressiveness across cancer types are poorly understood. Using ccRCC as a model, we show that Bap1 and Pbrm1 loss drives tumor grade. Furthermore, we show that the conversion from low grade to high grade can be promoted by activation of mTORC1.

Original languageEnglish (US)
Pages (from-to)900-917
Number of pages18
JournalCancer Discovery
Volume7
Issue number8
DOIs
StatePublished - 2017

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this